Hypoglycaemic drugs

Katp channels are the targets for two classes of therapeutic agents, hypoglycaemic drugs like glibencla-mide or nateglinide and potassium channel openers like... 

Around 40 years ago, the short-lived use of synthalin (II) as a hypoglycaemic drug [2] led to numerous studies on guanidines as potential insulin substitutes [3]. Synthalin itself was withdrawn when it was reported that it can cause liver damage [4], and the widespread interest in guanidines eventually lapsed until the introduction of guanethidine nearly 30 years later. 

Howes LG, Sundaresan P, Lykos D. Cardiovascular effects of oral hypoglycaemic drugs. Clin Exp Pharmacol Physiol 1996 23(3) 201-6. 

Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 1991 338(8771) 866-9. 

Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs 1977 13(l) 24-34. 

Irreversible MAOIs + oral hypoglycaemic drugs —> increased hypoglycaemic effect. 

HYPOGLYCAEMIC DRUGS CHROMIUM Chromium supplements may T risk of hypoglycaemia Chromium is necessary for the production of insulin Be aware... 

Note. For a review of the pharmacokinetics of sulphonylurea hypoglycaemic drugs see J. E. Jackson and R. Bressler, Drugs, 1981,22,211-245. 

We have pleasure in presenting nine reviews in this volume covering important advances in the chemistry and biology of a broad spectrum of medicinal topics. With the emergence of new insulin variants and some new synthetic hypoglycaemic drugs, a review of recent progress (Chapter 1) in the treatment of diabetes mellitus is timely. 

---